Arbutus Biopharma Corp
ABUS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001447028
No open-market purchases or sales by Arbutus Biopharma Corp insiders were filed in the last 90 days; 176 institutions reported holding it in 13F filings for Q2 2026, worth $674.9M in total; no superinvestor holds it.
Holders of 5% or more of ABUS
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Arbutus Biopharma Corp, largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Roivant Sciences Ltd. | 13D/A | 20.50%38.8M shares | 0.00 ppfrom 20.50% | Feb 18, 20252 filings | Feb 25, 2025 | SEC |
| Morgan Stanley | 13G/A | 13.50%25.9M shares | +2.10 ppfrom 11.40% | Feb 3, 20252 filings | Feb 11, 2026 | SEC |
| Two Seas Capital LP | 13G/A | 9.40%18.6M shares | +2.90 ppfrom 6.50% | Aug 13, 20253 filings | May 15, 2026 | SEC |
| Whitefort Capital Management, LP | 13D/A | 7.00%13.3M shares | – | Feb 21, 20251 filing | Feb 21, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
8 Schedule 13D and 13G filings on Arbutus Biopharma Corp, newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| May 15, 20265:29 PM ET | Two Seas Capital LPand 2 others | 13G/A | 9.40%18.6M shares | +2.90 ppfrom 6.50% | Mar 31, 2026 | SEC |
| Feb 17, 20264:21 PM ET | Two Seas Capital LPand 2 others | 13G/A | 6.50%12.6M shares | +1.10 ppfrom 5.40% | Dec 31, 2025 | SEC |
| Feb 11, 20261:45 PM ET | Morgan Stanleyand 1 other | 13G/A | 13.50%25.9M shares | +2.10 ppfrom 11.40% | Dec 31, 2025 | SEC |
| Aug 13, 20255:40 PM ET | Two Seas Capital LPand 2 others | 13G | 5.40%10.4M shares | New | Jun 30, 2025 | SEC |
| Feb 25, 20257:19 AM ET | Roivant Sciences Ltd. | 13D/A | 20.50%38.8M shares | 0.00 ppfrom 20.50% | Feb 21, 2025 | SEC |
| Feb 21, 20259:00 AM ET | Whitefort Capital Management, LPand 5 others | 13D/A | 7.00%13.3M shares | – | Feb 20, 2025 | SEC |
| Feb 18, 20255:21 PM ET | Roivant Sciences Ltd. | 13D/A | 20.50%38.8M shares | – | Feb 18, 2025 | SEC |
| Feb 3, 20253:26 PM ET | Morgan Stanleyand 1 other | 13G/A | 11.40%21.5M shares | – | Dec 31, 2024 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Arbutus Biopharma Corp shares.
No Form 144 notices for Arbutus Biopharma Corp are on file.